Iovance Biotherapeutics (IOVA) Debt/Equity Ratio: History & Chart

Iovance Biotherapeutics, Inc.(IOVA)

Biotechnology · San Carlos, CA

$13.30-0.85 (-6.01%)

Delayed quote: Oct 6, 2026, 11:55 AM EDT

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

San Carlos, CA

975 employees

www.iovance.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Frederick G. Vogt

View full financials

IOVA Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.06

DEBT TO EQUITY RATIO AVG TTM

0.07

DEBT TO EQUITY RATIO AVG 3Y

0.09

DEBT TO EQUITY RATIO AVG 5Y

0.11

DEBT TO EQUITY RATIO AVG 10Y

0.07

DEBT TO EQUITY RATIO AVG 15Y

0.05

DEBT TO EQUITY RATIO AVG 20Y

0.04

CURRENT VS TTM AVG

-10.43%

CURRENT VS 3Y AVG

-33.43%

CURRENT VS 5Y AVG

-43.51%

CURRENT VS 10Y AVG

-5.29%

CURRENT VS 15Y AVG

+32.39%

CURRENT VS 20Y AVG

+64.86%

SECTOR MEDIAN · HEALTHCARE

0.13

median of 641 covered companies

CURRENT VS SECTOR MEDIAN

-51.92%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Iovance Biotherapeutics, Inc. (IOVA)	$5.94B	0.06	0.07	0.09	0.11
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$6.01B	1.17	0.23	0.15	0.27
GRAIL Inc. (GRAL)vs ›	$6.06B	0.04	0.04	0.03	0.04
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.82B	0.01	0.02	0.02	0.02
CG Oncology Inc. (CGON)vs ›	$5.77B	0.01	0.01	0.04	0.11
RadNet, Inc. (RDNT)vs ›	$5.53B	1.99	1.81	2.63	3.97
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.53B	0.02	0.02	0.01	0.01
PTC Therapeutics, Inc. (PTCT)vs ›	$5.40B	N/A	441.80	221.15	147.72
Lantheus Holdings, Inc. (LNTH)vs ›	$6.51B	0.48	0.57	0.80	0.68
Doximity, Inc. (DOCS)vs ›	$5.35B	0.01	0.01	0.02	0.01

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Iovance Biotherapeutics, Inc. (IOVA)

$5.94B

0.06

0.07

0.09

0.11

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$6.01B

1.17

0.23

0.15

0.27

GRAIL Inc. (GRAL)vs ›

$6.06B

0.04

0.03

0.04

Kiniksa Pharmaceuticals International, plc (KNSA)vs ›

$5.82B

0.01

0.02

CG Oncology Inc. (CGON)vs ›

$5.77B

0.01

0.04

0.11

RadNet, Inc. (RDNT)vs ›

$5.53B

1.99

1.81

2.63

3.97

MiniMed Group, Inc. Common Stock (MMED)vs ›

$5.53B

0.02

0.01

PTC Therapeutics, Inc. (PTCT)vs ›

$5.40B

N/A

441.80

221.15

147.72

Lantheus Holdings, Inc. (LNTH)vs ›

$6.51B

0.48

0.57

0.80

0.68

Doximity, Inc. (DOCS)vs ›

$5.35B

0.01

0.02

0.01

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The debt to equity ratio for IOVA stock is 0.06.

Is Iovance Biotherapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.06 is 44% below its 5-year average of 0.11, near the low end of its 5-year range (0.06–0.20).

What is the TTM average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The TTM average debt to equity ratio for IOVA stock is 0.07.

What is the 3Y average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The 3Y average debt to equity ratio for IOVA stock is 0.09.

What is the 5Y average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The 5Y average debt to equity ratio for IOVA stock is 0.11.

What is the 10Y average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The 10Y average debt to equity ratio for IOVA stock is 0.07.

What is the 15Y average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The 15Y average debt to equity ratio for IOVA stock is 0.05.

What is the 20Y average debt to equity ratio for Iovance Biotherapeutics, Inc. (IOVA)?

The 20Y average debt to equity ratio for IOVA stock is 0.04.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.06
2026-03-31	0.07
2025-12-31	0.07
2025-09-30	0.07
2025-06-30	0.08
2025-03-31	0.07
2024-12-31	0.08
2024-09-30	0.10
2024-06-30	0.11
2024-03-31	0.12
2023-12-31	0.13
2023-09-30	0.12
2023-06-30	0.14
2023-03-31	0.12
2022-12-31	0.17
2022-09-30	0.20
2022-06-30	0.17
2022-03-31	0.14
2021-12-31	0.12
2021-09-30	0.10
2021-06-30	0.07
2021-03-31	0.08
2020-12-31	0.08
2020-09-30	0.02
2020-06-30	0.01
2020-03-31	0.04
2019-12-31	0.04
2019-09-30	0.04
2019-06-30	0.04
2019-03-31	0.03
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	0.00
2016-03-31	0.00
2015-12-31	0.00
2015-09-30	0.00
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.00
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	-0.55
2012-12-31	-0.57
2012-09-30	-0.39
2012-06-30	-0.37
2012-03-31	-0.29
2011-12-31	-0.39
2011-09-30	-0.46
2011-06-30	0.00
2011-03-31	0.00
2010-12-31	0.00
2010-09-30	0.00
2010-06-30	0.00
2010-03-31	0.00
2009-12-31	0.00
2009-09-30	0.00
2009-06-30	0.00
2009-03-31	0.00
2008-12-31	0.00
2008-09-30	0.00
2008-06-30	0.00
2008-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.06

2026-03-31

0.07

2025-12-31

0.07

2025-09-30

0.07

2025-06-30

0.08

2025-03-31

0.07

2024-12-31

0.08

2024-09-30

0.10

2024-06-30

0.11

2024-03-31

0.12

2023-12-31

0.13

2023-09-30

0.12

2023-06-30

0.14

2023-03-31

0.12

2022-12-31

0.17

2022-09-30

0.20

2022-06-30

0.17

2022-03-31

0.14

2021-12-31

0.12

2021-09-30

0.10

2021-06-30

0.07

2021-03-31

0.08

2020-12-31

0.08

2020-09-30

0.02

2020-06-30

0.01

2020-03-31

0.04

2019-12-31

0.04

2019-09-30

0.04

2019-06-30

0.04

2019-03-31

0.03

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

0.00

2016-03-31

0.00

2015-12-31

0.00

2015-09-30

0.00

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.00

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

-0.55

2012-12-31

-0.57

2012-09-30

-0.39

2012-06-30

-0.37

2012-03-31

-0.29

2011-12-31

-0.39

2011-09-30

-0.46

2011-06-30

0.00

2011-03-31

0.00

2010-12-31

0.00

2010-09-30

0.00

2010-06-30

0.00

2010-03-31

0.00

2009-12-31

0.00

2009-09-30

0.00

2009-06-30

0.00

2009-03-31

0.00

2008-12-31

0.00

2008-09-30

0.00

2008-06-30

0.00

2008-03-31

0.00

Debt to Equity Ratio: 0.06

IOVA Debt to Equity Ratio

IOVA Average Debt to Equity Ratio Chart

IOVA Current vs Average Debt to Equity Ratio Chart

IOVA Debt to Equity Ratio Metrics

IOVA Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

IOVA Debt to Equity Ratio History

Related Metrics